Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …

The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis,
presenting a broad range of challenges. To help address some of the main problems, the …

The global pandemic of SARS-CoV-2, the causative viral pathogen of COVID-19, has driven
the biomedical community to action—to uncover and develop antiviral interventions. One …

Patients and physicians worldwide are facing tremendous health care hazards that are
caused by the ongoing severe acute respiratory distress syndrome coronavirus 2 (SARS …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the novel viral disease COVID-19. With no approved therapies, this pandemic illustrates the …

The novel coronavirus infection that initially found at the end of 2019 has attracted great
attention. So far, the number of infectious cases has increased globally to more than 100 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …

Remdesivir (RDV), a single diastereomeric monophosphoramidate prodrug that inhibits viral
RNA polymerases, has potent in vitro antiviral activity against severe acute respiratory …

Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved
therapeutics are available. The CoV nsp14 exoribonuclease (ExoN) has complicated …